NCT01440582 is a Phase 1 clinical trial of Panobinostat in Myeloma, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01440582?

NCT01440582 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01440582?

Interventions in NCT01440582: Panobinostat, Bortezomib, Lenalidomide, Dexamethasone, Symptom Questionnaire.

Is NCT01440582 still recruiting?

NCT01440582 is currently completed. Last updated 4 March 2019.

Last reviewed 2019-03-04 · How we verify

NCT01440582

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed Phase 1 Last updated 4 March 2019

What this trial tests

Phase 1 trial testing Panobinostat in Myeloma in 77 participants. Completed in 28 February 2019.

Timeline

18 February 2013

Primary endpoint
28 February 2019

28 February 2019

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	77
Start date	18 February 2013
Primary completion	28 February 2019
Estimated completion	28 February 2019
Sites	1 location across United States

Drugs / interventions tested

Panobinostat (PANOBINOSTAT) — full drug profile →
Bortezomib (bortezomib) — full drug profile →
Lenalidomide — full drug profile →
Dexamethasone (dexamethasone) — full drug profile →
Symptom Questionnaire

Conditions studied

Myeloma — all drugs for Myeloma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of the drug panobinostat that can be given in combination with the drugs Velcade (bortezomib), Revlimid (lenalidomide), and Decadron (dexamethasone) to patients with MM. The safety of this drug combination will also be studied. Panobinostat is designed to cause chemical changes in different groups of proteins that are attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or cause the cancer cells to die. Bortezomib is designed to block a protein that causes cells to grow. This may cause cancer cells to die. Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may slow the growth of cancer cells. Dexamethasone is a corticosteroid that is similar to a natural hormone made by your body. Dexamethasone is often given to MM patients in combination with other chemotherapy to treat cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R, Conte M, Altucci L. · · 2015 · cited 91× · PMID 24382114 · DOI 10.1089/ars.2013.5776
Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
Zhao A, Zhou H, Yang J, Li M, et al · · 2023 · cited 81× · PMID 36797244 · DOI 10.1038/s41392-023-01342-6
Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives.
Pu J, Liu T, Wang X, Sharma A, et al · · 2024 · cited 36× · PMID 38654286 · DOI 10.1186/s40164-024-00507-5
The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian D, Mo CC, Landgren O, Richardson PG. · · 2020 · cited 25× · PMID 32501533 · DOI 10.1111/bjh.16764
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
Sengsayadeth S, Malard F, Savani BN, Garderet L, et al · · 2017 · cited 25× · PMID 28338672 · DOI 10.1038/bcj.2017.23
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE, Shah JJ, Lee HC, Weber DM, et al · · 2018 · cited 14× · PMID 30501870 · DOI 10.1016/s2352-3026(18)30174-1
Investigating the Interplay between Myeloma Cells and Bone Marrow Stromal Cells in the Development of Drug Resistance: Dissecting the Role of Epigenetic Modifications.
Schütt J, Nägler T, Schenk T, Brioli A. · · 2021 · cited 8× · PMID 34439223 · DOI 10.3390/cancers13164069
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.
Redic KA, Hough SM, Price EM. · · 2016 · cited 8× · PMID 27274274 · DOI 10.2147/ott.s87962

Verify or expand the search:

Other trials of Panobinostat

Trials testing the same drug.

NCT05725200 — Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer · Phase 2 · recruiting
NCT04341311 — Phase I Study of Marizomib + Panobinostat for Children With DIPG · Phase 1 · terminated
NCT03878524 — Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · Phase 1 · terminated
NCT04897880 — A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT · Phase 2 · terminated
NCT04326764 — Panobinostat Maintenance After HSCT fo High-risk AML and MDS · Phase 3 · terminated

Other recruiting trials for Myeloma

Currently open trials in the same condition.

NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT07106671 — A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma · Phase 2 · recruiting
NCT07052916 — A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties · NA · recruiting
NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
NCT07202091 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 2, PHASE3 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01440582 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 4 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01440582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing